Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Gross

Ophthalmology Fairhope, AL Medical Doctor

NPI 1902890544 CMS profile 313613

411 N Section St, Fairhope, AL 36532

Open in the dashboard

General payments

$142,874

200 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$111,229 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Ronald Gross of Fairhope, AL is reported in the CMS Open Payments database as having received $142,874 across 200 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $111,229 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $163 2
2024 General $443 4
2023 General $276 2
2022 General $150 1
2021 General $21,007 13
2020 General $29,727 27
2019 General $91,109 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Gross
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Ronald Gross were reported at $163. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Ronald Gross Ophthalmology median Middle half National median
2019 $91,109 $258 $104–$655 $163
2020 $29,727 $126 $45–$321 $114
2021 $21,007 $205 $76–$534 $132
2022 $150 $266 $100–$678 $149
2023 $276 $308 $117–$745 $160
2024 $443 $340 $127–$846 $164
2025 $163 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerie Pharmaceuticals, Inc. $88,271 99 payments
  2. Allergan Inc. $46,718 86 payments
  3. Glaukos Corporation $6,734 3 payments
  4. Alcon Vision LLC $296 2 payments
  5. New World Medical,Inc. $276 2 payments
  6. AbbVie, Inc. $156 2 payments
  7. CVRx, Inc. $150 1 payment
  8. Genentech, Inc. $138 2 payments
  9. TearLab Corp $96 1 payment
  10. Tarsus Pharmaceuticals, Inc. $21 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,990 29 payments
  2. Consulting Fee $30,950 13 payments
  3. Travel and Lodging $17,625 96 payments
  4. Food and Beverage $4,310 62 payments
Products named General payments · program years 2019–2025
  1. Rocklatan Glaucoma $50,033 66 payments
  2. LUMIGAN $40,573 81 payments
  3. rocklatan Glaucoma $38,207 32 payments
  4. rhopressa Glaucoma $38,197 31 payments
  5. Rhopressa Glaucoma $30,514 45 payments
  6. COMBIGAN $20,169 37 payments
  7. iStent inject Trabecular Micro-Bypass Stent System $6,600 2 payments
  8. RESTASIS $5,000 2 payments
  9. XEN GLAUCOMA TREATMENT SYSTEM $156 2 payments
  10. Clareon $153 1 payment
  11. Other $697 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record